These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15876908)

  • 1. An open trial of naltrexone in the treatment of depersonalization disorder.
    Simeon D; Knutelska M
    J Clin Psychopharmacol; 2005 Jun; 25(3):267-70. PubMed ID: 15876908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial.
    Bohus MJ; Landwehrmeyer GB; Stiglmayr CE; Limberger MF; Böhme R; Schmahl CG
    J Clin Psychiatry; 1999 Sep; 60(9):598-603. PubMed ID: 10520978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depersonalization disorder: pharmacological approaches.
    Sierra M
    Expert Rev Neurother; 2008 Jan; 8(1):19-26. PubMed ID: 18088198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of naltrexone for dissociative symptoms in borderline personality disorder.
    Schmahl C; Kleindienst N; Limberger M; Ludäscher P; Mauchnik J; Deibler P; Brünen S; Hiemke C; Lieb K; Herpertz S; Reicherzer M; Berger M; Bohus M
    Int Clin Psychopharmacol; 2012 Jan; 27(1):61-8. PubMed ID: 22002175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lamotrigine as an add-on treatment for depersonalization disorder: a retrospective study of 32 cases.
    Sierra M; Baker D; Medford N; Lawrence E; Patel M; Phillips ML; David AS
    Clin Neuropharmacol; 2006; 29(5):253-8. PubMed ID: 16960469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lamotrigine in the immediate treatment of outpatients with depersonalization disorder without psychiatric comorbidity: randomized, double-blind, placebo-controlled study.
    Aliyev NA; Aliyev ZN
    J Clin Psychopharmacol; 2011 Feb; 31(1):61-5. PubMed ID: 21192145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of naloxone therapy on depersonalization: a pilot study.
    Nuller YL; Morozova MG; Kushnir ON; Hamper N
    J Psychopharmacol; 2001 Jun; 15(2):93-5. PubMed ID: 11448093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of dissociative symptoms in borderline patients with naltrexone].
    Schmahl C; Stiglmayr C; Böhme R; Bohus M
    Nervenarzt; 1999 Mar; 70(3):262-4. PubMed ID: 10231814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive-affective neuroscience of depersonalization.
    Stein DJ; Simeon D
    CNS Spectr; 2009 Sep; 14(9):467-71. PubMed ID: 19890227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
    Anton RF; O'Malley SS; Ciraulo DA; Cisler RA; Couper D; Donovan DM; Gastfriend DR; Hosking JD; Johnson BA; LoCastro JS; Longabaugh R; Mason BJ; Mattson ME; Miller WR; Pettinati HM; Randall CL; Swift R; Weiss RD; Williams LD; Zweben A;
    JAMA; 2006 May; 295(17):2003-17. PubMed ID: 16670409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of dissociative symptoms with opioid antagonists: a systematic review.
    Escamilla I; Juan N; Peñalva C; Sánchez-Llorens M; Renau J; Benito A; Haro G
    Eur J Psychotraumatol; 2023; 14(2):2265184. PubMed ID: 37860852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges.
    Grant JE; Kim SW; Hartman BK
    J Clin Psychiatry; 2008 May; 69(5):783-9. PubMed ID: 18384246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylphenidate in depersonalization disorder: a case report.
    Foguet Q; Alvárez MJ; Castells E; Arrufat F
    Actas Esp Psiquiatr; 2011; 39(1):75-8. PubMed ID: 21274825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naltrexone and disulfiram in patients with alcohol dependence and current depression.
    Petrakis I; Ralevski E; Nich C; Levinson C; Carroll K; Poling J; Rounsaville B;
    J Clin Psychopharmacol; 2007 Apr; 27(2):160-5. PubMed ID: 17414239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term treatment of post-traumatic stress disorder with naltrexone: an open-label preliminary study.
    Lubin G; Weizman A; Shmushkevitz M; Valevski A
    Hum Psychopharmacol; 2002 Jun; 17(4):181-5. PubMed ID: 12404685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of depersonalization with serotonin reuptake blockers.
    Hollander E; Liebowitz MR; DeCaria C; Fairbanks J; Fallon B; Klein DF
    J Clin Psychopharmacol; 1990 Jun; 10(3):200-3. PubMed ID: 2115893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opioid antagonists in the treatment of impulse-control disorders.
    Kim SW
    J Clin Psychiatry; 1998 Apr; 59(4):159-64. PubMed ID: 9590665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examination of the pathological dissociation taxon in depersonalization disorder.
    Simeon D; Knutelska M; Nelson D; Guralnik O; Schmeidler J
    J Nerv Ment Dis; 2003 Nov; 191(11):738-44. PubMed ID: 14614341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of pruritus with topically applied opiate receptor antagonist.
    Bigliardi PL; Stammer H; Jost G; Rufli T; Büchner S; Bigliardi-Qi M
    J Am Acad Dermatol; 2007 Jun; 56(6):979-88. PubMed ID: 17320241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label study of naltrexone in the treatment of kleptomania.
    Grant JE; Kim SW
    J Clin Psychiatry; 2002 Apr; 63(4):349-56. PubMed ID: 12000210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.